Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.46% | 11.10% | -4.46% | 26.88% | 11.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.46% | 11.10% | -4.46% | 26.88% | 11.33% |
| Cost of Revenue | 37.79% | 28.20% | 11.32% | 37.37% | 12.45% |
| Gross Profit | 22.77% | -6.34% | -21.45% | 14.62% | 10.17% |
| SG&A Expenses | 20.56% | 22.78% | 5.92% | 30.02% | 8.93% |
| Depreciation & Amortization | 36.83% | -9.09% | -18.14% | -7.05% | -4.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.43% | 20.56% | 4.76% | 30.61% | 8.70% |
| Operating Income | -80.03% | -180.74% | -295.54% | -3,366.39% | 238.68% |
| Income Before Tax | -412.20% | -2,265.11% | 94.75% | 129.27% | -93.28% |
| Income Tax Expenses | 254.78% | -211.30% | 6.56% | -52.22% | 174.55% |
| Earnings from Continuing Operations | -4,517.98% | -542.81% | 145.15% | 142.89% | -99.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4,517.98% | -542.81% | 145.15% | 142.89% | -99.13% |
| EBIT | -80.03% | -180.74% | -295.54% | -3,366.39% | 238.68% |
| EBITDA | 9.90% | -52.58% | -62.73% | -20.19% | 11.55% |
| EPS Basic | -4,700.00% | -554.29% | 145.95% | 144.26% | -99.11% |
| Normalized Basic EPS | -0.97% | -1,425.00% | -100.45% | -2,733.33% | 19.77% |
| EPS Diluted | -4,933.33% | -543.84% | 141.74% | 140.76% | -99.11% |
| Normalized Diluted EPS | -0.97% | -1,425.00% | -100.45% | -2,733.33% | 19.77% |
| Average Basic Shares Outstanding | -1.46% | -1.68% | -1.51% | -3.07% | -4.82% |
| Average Diluted Shares Outstanding | -1.46% | -1.68% | -1.08% | -2.68% | -5.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |